GlobalData’s research reveals that North America accounted for 51.7% of cardiomyopathy drug sales in the 68M in 2021 and is expected to account for 54.2% in 2031.

Sarah Bundra, Pharmaceutical Analyst at GlobalData, comments: “GlobalData research finds that the US is set to dominate the cardiomyopathy landscape because of the country’s high prevalence of dilated cardiomyopathy (DCM) relative to the other markets in the **7MM, as well as the higher price tag on US marketed therapeutics.”

GlobalData also shows that the second highest contributing market in the 68M is the APAC region, generating 33.2% of global cardiomyopathy sales in 2021 and expected to contribute 31.2% in 2031.

Bundra continues: “APAC’s dominance in the space is primarily due to the high volume of drug sales in China, which totaled $789.05 million in 2021 and is expected to be $2.24 billion in 2031.”

Previous research by GlobalData indicated that growth in the cardiomyopathies market in the 7MM could be primarily attributed to the release of Bristol Myers Squibb’s Camzyos (mavacamten) and the launch of Cytokinetics’ aficamten—both of which are myosin inhibitors indicated for the management of obstructive hypertrophic cardiomyopathy (HCM).

Bundra adds: “Camzyos and aficamten are unique in their mechanism of action, as myosin inhibitors, and also in their target indication. Previous to these two drugs, obstructive hypertrophic cardiomyopathy did not have therapeutic options.”